Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
3.170
+0.060 (1.93%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Niagen Bioscience Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 251 | 509 | 406 | 108 | 125 | 256 | |
Market Cap Growth | -67.41% | 25.25% | 277.18% | -14.15% | -50.96% | -14.02% |
Enterprise Value | 187 | 448 | 377 | 85 | 117 | 226 |
Last Close Price | 3.17 | 6.36 | 5.30 | 1.43 | 1.68 | 3.74 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.67 | 29.26 | 47.50 | - | - | - |
Forward PE | 34.46 | 27.81 | 50.28 | 160.00 | 160.00 | 160.00 |
PS Ratio | 1.95 | 3.93 | 4.08 | 1.29 | 1.74 | 3.79 |
PB Ratio | 3.04 | 6.65 | 8.81 | 3.78 | 4.37 | 8.06 |
P/TBV Ratio | 3.26 | 7.18 | 8.88 | 3.85 | 4.48 | 8.29 |
P/FCF Ratio | 44.30 | 38.50 | 33.99 | 15.45 | - | - |
P/OCF Ratio | 42.25 | 37.67 | 33.54 | 15.13 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.45 | 3.46 | 3.78 | 1.01 | 1.62 | 3.35 |
EV/EBITDA Ratio | 19.51 | 29.68 | 44.12 | - | - | - |
EV/EBIT Ratio | 21.72 | 31.31 | 48.76 | - | - | - |
EV/FCF Ratio | 32.97 | 33.87 | 31.54 | 12.17 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.04 | 0.06 | 0.12 | 0.15 | 0.15 |
Debt / EBITDA Ratio | 0.21 | 0.17 | 0.27 | - | - | - |
Debt / FCF Ratio | 0.41 | 0.21 | 0.22 | 0.47 | - | - |
Net Debt / Equity Ratio | -0.78 | -0.81 | -0.91 | -0.84 | -0.56 | -0.73 |
Net Debt / EBITDA Ratio | -6.70 | -4.10 | -4.90 | 5.23 | 0.91 | 0.90 |
Net Debt / FCF Ratio | -11.32 | -4.68 | -3.50 | -3.43 | 1.04 | 0.95 |
Asset Turnover | 1.30 | 1.48 | 1.62 | 1.53 | 1.29 | 1.40 |
Inventory Turnover | 2.63 | 3.12 | 3.21 | 2.25 | 2.07 | 2.05 |
Quick Ratio | 5.00 | 3.73 | 2.91 | 1.57 | 1.61 | 1.89 |
Current Ratio | 6.50 | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 |
Return on Equity (ROE) | 21.80% | 28.35% | 22.94% | -17.29% | -54.77% | -112.68% |
Return on Assets (ROA) | 5.44% | 10.23% | 7.84% | -6.42% | -20.81% | -35.18% |
Return on Invested Capital (ROIC) | 44.00% | 144.16% | 169.60% | -65.11% | -176.99% | -542.87% |
Return on Capital Employed (ROCE) | 9.40% | 16.50% | 15.40% | -16.30% | -51.50% | -67.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.36% | 3.42% | 2.10% | -4.59% | -13.19% | -10.61% |
FCF Yield | 2.26% | 2.60% | 2.94% | 6.47% | -12.31% | -9.61% |
Buyback Yield / Dilution | -2.25% | -9.36% | -4.19% | -7.54% | -3.79% | -10.02% |